Literature DB >> 21083186

A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma.

Warunee Hanpithakpong1, Benjamas Kamanikom, Pratap Singhasivanon, Nicholas J White, Nicholas Pj Day, Niklas Lindegardh.   

Abstract

BACKGROUND: Artemether-lumefantrine is the most widely recommended artemisinin-based combination treatment for falciparum malaria. Quantification of artemether and its metabolite dihydroartemisinin in biological matrices has traditionally been difficult, with sensitivity being an issue.
RESULTS: A high-throughput bioanalytical method for the analysis of artemether and its metabolite dihydroartemisinin in human plasma using solid-phase extraction in the 96-well plate format and liquid chromatography coupled to positive ion mode tandem mass spectroscopy has been developed and validated according to US FDA guidelines. The method uses 50 µl plasma and covers the calibration range 1.43-500 ng/ml with a limit of detection at 0.36 ng/ml.
CONCLUSIONS: The developed liquid chromatography-tandem mass spectrometry assay is more sensitive than all previous methods despite using a lower plasma volume (50 µl) and is highly suitable for clinical studies where plasma volumes are limited, such as pediatric trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 21083186     DOI: 10.4155/bio.09.6

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  15 in total

Review 1.  Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Authors:  Carol Hopkins Sibley; Ric N Price
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-20       Impact factor: 4.077

2.  Pharmacokinetics of artesunate alone and in combination with sulfadoxine/pyrimethamine in healthy Sudanese volunteers.

Authors:  Kamal M Matar; Abdelmoneim I Awad; Sakina B Elamin
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

3.  Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method.

Authors:  Liusheng Huang; Alexander Olson; David Gingrich; Francesca T Aweeka
Journal:  Bioanalysis       Date:  2013-06       Impact factor: 2.681

4.  Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma.

Authors:  Liusheng Huang; Anura L Jayewardene; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  J Pharm Biomed Anal       Date:  2009-07-07       Impact factor: 3.935

5.  Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine.

Authors:  Shabana Ali; Muzammil H Najmi; Joel Tarning; Niklas Lindegardh
Journal:  Malar J       Date:  2010-10-11       Impact factor: 2.979

6.  Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays.

Authors:  Silvia Parapini; Piero Olliaro; Visweswaran Navaratnam; Donatella Taramelli; Nicoletta Basilico
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

7.  Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.

Authors:  Rob W van der Pluijm; Rupam Tripura; Richard M Hoglund; Aung Pyae Phyo; Dysoley Lek; Akhter Ul Islam; Anupkumar R Anvikar; Parthasarathi Satpathi; Sanghamitra Satpathi; Prativa Kumari Behera; Amar Tripura; Subrata Baidya; Marie Onyamboko; Nguyen Hoang Chau; Yok Sovann; Seila Suon; Sokunthea Sreng; Sivanna Mao; Savuth Oun; Sovannary Yen; Chanaki Amaratunga; Kitipumi Chutasmit; Chalermpon Saelow; Ratchadaporn Runcharern; Weerayuth Kaewmok; Nhu Thi Hoa; Ngo Viet Thanh; Borimas Hanboonkunupakarn; James J Callery; Akshaya Kumar Mohanty; James Heaton; Myo Thant; Kripasindhu Gantait; Tarapada Ghosh; Roberto Amato; Richard D Pearson; Christopher G Jacob; Sónia Gonçalves; Mavuto Mukaka; Naomi Waithira; Charles J Woodrow; Martin P Grobusch; Michele van Vugt; Rick M Fairhurst; Phaik Yeong Cheah; Thomas J Peto; Lorenz von Seidlein; Mehul Dhorda; Richard J Maude; Markus Winterberg; Nguyen Thanh Thuy-Nhien; Dominic P Kwiatkowski; Mallika Imwong; Podjanee Jittamala; Khin Lin; Tin Maung Hlaing; Kesinee Chotivanich; Rekol Huy; Caterina Fanello; Elizabeth Ashley; Mayfong Mayxay; Paul N Newton; Tran Tinh Hien; Neena Valecha; Frank Smithuis; Sasithon Pukrittayakamee; Abul Faiz; Olivo Miotto; Joel Tarning; Nicholas P J Day; Nicholas J White; Arjen M Dondorp
Journal:  Lancet       Date:  2020-03-11       Impact factor: 202.731

8.  Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.

Authors:  Joel Tarning; Frank Kloprogge; Patrice Piola; Mehul Dhorda; Sulaiman Muwanga; Eleanor Turyakira; Nitra Nuengchamnong; François Nosten; Nicholas P J Day; Nicholas J White; Philippe J Guerin; Niklas Lindegardh
Journal:  Malar J       Date:  2012-08-22       Impact factor: 2.979

9.  Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.

Authors:  Joel Tarning; Frank Kloprogge; Mehul Dhorda; Vincent Jullien; Francois Nosten; Nicholas J White; Philippe J Guerin; Patrice Piola
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

10.  Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

Authors:  Liusheng Huang; Vincent Carey; Jane C Lindsey; Florence Marzan; David Gingrich; Bobbie Graham; Linda Barlow-Mosha; Phionah K Ssemambo; Portia Kamthunzi; Sharon Nachman; Sunil Parikh; Francesca T Aweeka
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.